Abstract Details

Title Efficacy and Safety of Corticosteroid in Adult Facial Nerve Palsy Through House-Brackmann Scale Measurement: A Meta-Analysis of Randomized Controlled Trials

Topic General Neurology

Presentation(s) P2 - Poster Session 2 (8:00 AM-9:00 AM)

Poster/Presentation
Number 2-011

Objective

to provide information on the efficacy and safety of corticosteroid use in treating adult FNP patients.

Background The management of facial nerve palsy (FNP) remains a subject of debate. Various studies have shown that corticosteroids are a promising therapeutic agent; however, some research results are inconsistent. We conducted a meta-analysis of randomized controlled trials (RCTs) to provide information on the efficacy and safety of corticosteroid use in treating adult FNP patients.

Design/Methods

An online search through electronic journals, including Cochrane Library, PubMed, Science Direct, PlosOne, and ProQuest was conducted to compare corticosteroid and placebo for FNP patients. The primary outcome was the efficacy of corticosteroids in achieving FNP recovery at the 3rd, 6th, and 9th months post-treatment. The House-Brackmann Scale measurement of 1 was used as an indication for recovery. The secondary outcome includes the adverse effects comparison. The final analysis included 5 RCTs with 1064 adult patients; and 532 patients in both the corticosteroid and placebo group.

Results This meta-analysis concludes significant difference favouring the corticosteroid group in achieving recovery at 3 (RR 1.20; 95% CI 0.89 to 1.60), 6 (RR 1.16; 95% CI 1.02 to 1.32), and 9 months (RR 1.11; 95% CI 1.04 to 1.19). Another sub-group analysis for FNP of idiopathic cause within 0-72 hours onset showed a significant difference favouring the corticosteroid group in achieving recovery at 3 months (RR 1.27; 95% CI 1.16 to 1.39). However, no significant differences were found in the amount of total adverse effects (RR 0.93; 95% CI 0.79 to 1.08).

Conclusions

This study suggests that corticosteroid utilization for adult FNP patients results in a significantly better recovery rate with a similar safety profile compared to placebo therapy. Further studies are required to assess treatment duration, dose, and indications for clinical use.

Authors/Disclosures
Joshua Limantoro, MD PRESENTER	Mr. Limantoro has nothing to disclose.
Ayu M. Sari	Miss Sari has nothing to disclose.
Made Ratna Komala Cahyani, SKed	Ms. Ratna Komala Cahyani has nothing to disclose.
Khaled Moghib, MBBS	Dr. Moghib has nothing to disclose.

��ɫ��

��ɫ��